Home
Products
Iniparib
| Product Name | Iniparib |
| Price: | Inquiry |
| Catalog No.: | CN00125 |
| CAS No.: | 160003-66-7 |
| Molecular Formula: | C7H5IN2O3 |
| Molecular Weight: | 292.03 g/mol |
| Purity: | >=98% |
| Type of Compound: | Alkaloids |
| Physical Desc.: | Powder |
| Source: | |
| Solvent: | Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc. |
| SMILES: | [O-][N+](=O)c1cc(ccc1I)C(=O)N |
| Contact us | |
|---|---|
| First Name: | |
| Last Name: | |
| E-mail: | |
| Question: | |
| Description | Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer. |
| Target | PARP1 |
| In Vitro | Iniparib nonselectively modifies cysteine-containing proteins in tumor cells[1]. Iniparib (100 μM) weakly inhibits SSB repair, and the inhibition can be reversed by knockdown of PARP1[2]. Iniparib in combination with cisplatin is cytotoxic to Myc/MDA-231 with EMT changes[3]. |
| Cell Assay | For nine day cell proliferation assay, MDA-MB-436 and MDA-MB-231 cells are plated at 2000 and 500 cells/well respectively in a 96-well plate and treated with veliparib, cmpd-A, cmpd-C, Iniparib or Iniparib-met at 0, 0.0001, 0.01,0.1, 1 or 10 μM for nine days. For five day cell proliferation assay, MDAMB-231 and MDA-MB-436 cells are plated at 1000 and 4000 cells/well respectively in a 96-well plate and treated with Iniparib or Iniparib-met at 0. 0.1, 0.3, 1, 3 or 10 μM in the presence of 0, 1.8, 3.75, or 7.5 µM BSO for 5 days. DLD1+/+ and DLD1-/- cells are plated at 1000 cells/well in a 96-well plate and treated with TMZ at 0, 0.003, 0.01, 0.03, 0.1, 0.3 or 1 mM in the presence of 0, 0.005, 0.05, 0.5, or 5 µM veliparib, or Iniparib for five days. After treatment, cell titer glow is carried out[1]. |
| Density | 2.1±0.1 g/cm3 |
| Boiling Point | 344.8±32.0 °C at 760 mmHg |
| Flash Point | 162.3±25.1 °C |
| Exact Mass | 291.934479 |
| PSA | 88.91000 |
| LogP | 1.71 |
| Vapour Pressure | 0.0±0.8 mmHg at 25°C |
| Storage condition | room temp |